Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Moderna (MRNA) ended the recent trading session at $31.25, demonstrating a -2.95% change from the preceding day's closing price. This move lagged the S&P 500's daily loss of 0.01%. Elsewhere, the Dow ...

Moderna, already in cash-saving mode amid uncertain vaccine dynamics, is backing off from its plans to construct an mRNA drug ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

The capped upside and unlimited downside risk make MRNY unattractive unless Moderna's share price stabilizes and recovers meaningfully. Current distributions are high (near 100% yield), but payouts ...

The company was pleased to report the findings of a late-stage clinical trial of its advanced flu vaccine. Moderna (NASDAQ: MRNA), the next-generation healthcare company most famous for developing ...

Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna on June 30. The company’s shares closed yesterday at $28.69. Foroohar covers the Healthcare sector, focusing on stocks such ...

Moderna’s new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major trial.

(The Hill) – Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly ...